0000899243-20-019869.txt : 20200721
0000899243-20-019869.hdr.sgml : 20200721
20200721193542
ACCESSION NUMBER: 0000899243-20-019869
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200717
FILED AS OF DATE: 20200721
DATE AS OF CHANGE: 20200721
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kakkar Rahul
CENTRAL INDEX KEY: 0001817416
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39381
FILM NUMBER: 201039940
MAIL ADDRESS:
STREET 1: C/O PANDION THERAPEUTICS, INC.
STREET 2: 134 COOLIDGE AVE., 2ND FLOOR
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pandion Therapeutics, Inc.
CENTRAL INDEX KEY: 0001807901
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 833015614
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 134 COOLIDGE AVENUE
STREET 2: 2ND FLOOR
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-393-5925
MAIL ADDRESS:
STREET 1: 134 COOLIDGE AVENUE
STREET 2: 2ND FLOOR
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: Pandion Therapeutics Holdco LLC
DATE OF NAME CHANGE: 20200327
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-17
0
0001807901
Pandion Therapeutics, Inc.
PAND
0001817416
Kakkar Rahul
C/O PANDION THERAPEUTICS, INC.,
134 COOLIDGE AVENUE
WATERTOWN
MA
02472
1
1
0
0
Chief Executive Officer
Common Stock
2020-07-21
4
C
0
21133
A
702515
I
By Shah-Kakkar Holdings, LLC
Common Stock
2020-07-21
4
P
0
14000
18.00
A
14000
D
Stock Option (right to buy)
18.00
2020-07-17
4
A
0
27181
0.00
A
2030-07-16
Common Stock
27181
27181
D
Stock Option (right to buy)
18.00
2020-07-17
4
A
0
221067
0.00
A
2030-07-16
Common Stock
221067
221067
D
Stock Option (right to buy)
18.00
2020-07-17
4
A
0
100493
0.00
A
2030-07-16
Common Stock
100493
100493
D
Series B Preferred Stock
2020-07-21
4
C
0
107768
0.00
D
Common Stock
21133
0
I
By Shah-Kakkar Holdings, LLC
The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
Represents shares purchased through a directed share program in connection with the initial public offering of Pandion Therapeutics, Inc.'s common stock, which closed on July 21, 2020. These shares of common stock were purchased at the public offering price of $18.00 per share.
This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on August 5, 2020, with the remainder of the shares vesting in equal monthly installments following August 5, 2020 through August 5, 2023, subject to the reporting person's continued service on each applicable vesting date.
This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on May 21, 2021, with the remainder of the shares vesting in equal monthly installments following May 21, 2021 through May 21, 2024, subject to the reporting person's continued service on each applicable vesting date.
This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on June 25, 2021, with the remainder of the shares vesting in equal monthly installments following June 25, 2021 through June 25, 2024, subject to the reporting person's continued service on each applicable vesting date.
/s/ Edward Freedman, as attorney-in-fact for Rahul Kakkar
2020-07-21